CL2008003036A1 - Composicion farmaceutica acuosa que comprende 4-[(4-clorofenil)metil]-2-({(2r)-1-[4-(4-{[3-(hexahidro-1h-azepin-1-il)propil]oxi}fenil)butil]-2-pirrolidinil}metil)-1(2h)-ftalazinona; envase que la comprende; y uso para el tratamiento de enfermedades inflamatorias y/o alergicas tal como rinitis alergica. - Google Patents

Composicion farmaceutica acuosa que comprende 4-[(4-clorofenil)metil]-2-({(2r)-1-[4-(4-{[3-(hexahidro-1h-azepin-1-il)propil]oxi}fenil)butil]-2-pirrolidinil}metil)-1(2h)-ftalazinona; envase que la comprende; y uso para el tratamiento de enfermedades inflamatorias y/o alergicas tal como rinitis alergica.

Info

Publication number: CL2008003036A1
Authority: CL; Chile
Prior art keywords: methyl; phthalazinone; azepin; hexahydro; pyrrolidinyl
Prior art date: 2007-10-16

Application number

CL2008003036A

Other languages

English (en)

Spanish (es)

Inventor

Simon Teanby Hodgson

Ashley Paul Hancock

Leanda Jane Kindon

Gavin Bone

Richard Orlando Brown

Paul Martin Gore

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-16

Filing date

2008-10-14

Publication date

2009-05-08

2008-10-14 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2009-05-08 Publication of CL2008003036A1 publication Critical patent/CL2008003036A1/es

Links

YANGEESWIGIKOP-UUWRZZSWSA-N 2-[[(2r)-1-[4-[4-[3-(azepan-1-yl)propoxy]phenyl]butyl]pyrrolidin-2-yl]methyl]-4-[(4-chlorophenyl)methyl]phthalazin-1-one Chemical compound C1=CC(Cl)=CC=C1CC(C1=CC=CC=C1C1=O)=NN1C[C@@H]1N(CCCCC=2C=CC(OCCCN3CCCCCC3)=CC=2)CCC1 YANGEESWIGIKOP-UUWRZZSWSA-N 0.000 title abstract 2
206010039085 Rhinitis allergic Diseases 0.000 title abstract 2
208000026935 allergic disease Diseases 0.000 title abstract 2
201000010105 allergic rhinitis Diseases 0.000 title abstract 2
208000027866 inflammatory disease Diseases 0.000 title abstract 2
230000002757 inflammatory effect Effects 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

CL2008003036A 2007-10-16 2008-10-14 Composicion farmaceutica acuosa que comprende 4-[(4-clorofenil)metil]-2-({(2r)-1-[4-(4-{[3-(hexahidro-1h-azepin-1-il)propil]oxi}fenil)butil]-2-pirrolidinil}metil)-1(2h)-ftalazinona; envase que la comprende; y uso para el tratamiento de enfermedades inflamatorias y/o alergicas tal como rinitis alergica. CL2008003036A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US98022607P	2007-10-16	2007-10-16
US5723008P	2008-05-30	2008-05-30

Publications (1)

Publication Number	Publication Date
CL2008003036A1 true CL2008003036A1 (es)	2009-05-08

Family

ID=40198721

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2008003036A CL2008003036A1 (es)	2007-10-16	2008-10-14	Composicion farmaceutica acuosa que comprende 4-[(4-clorofenil)metil]-2-({(2r)-1-[4-(4-{[3-(hexahidro-1h-azepin-1-il)propil]oxi}fenil)butil]-2-pirrolidinil}metil)-1(2h)-ftalazinona; envase que la comprende; y uso para el tratamiento de enfermedades inflamatorias y/o alergicas tal como rinitis alergica.

Country Status (6)

Country	Link
AR (1)	AR068988A1 (fr)
CL (1)	CL2008003036A1 (fr)
PE (1)	PE20091089A1 (fr)
TW (1)	TW200932243A (fr)
UY (1)	UY31400A1 (fr)
WO (1)	WO2009050159A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0811447D0 (en) *	2008-06-20	2008-07-30	Glaxo Group Ltd	Formulations
ES2722926T3 (es) *	2012-12-17	2019-08-20	Glaxo Group Ltd	Combinación de levocabastina y furoato de fluticasona para el tratamiento de condiciones inflamatorias y/o alérgicas
EP4251148A1 (fr)	2020-11-27	2023-10-04	Richter Gedeon Nyrt.	Antagonistes/agonistes inverses du récepteur h3 de l'histamine pour le traitement d'un trouble du spectre autistique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6777399B2 (en) *	2000-08-05	2004-08-17	Smithkline Beecham Corporation	Anti-inflammatory androstane derivative compositions
GB0507165D0 (en) *	2005-04-08	2005-05-18	Glaxo Group Ltd	Novel crystalline pharmaceutical product
EA200801996A1 (ru) *	2006-04-20	2009-04-28	Глаксо Груп Лимитед	2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов

2008
- 2008-10-14 TW TW097139419A patent/TW200932243A/zh unknown
- 2008-10-14 WO PCT/EP2008/063781 patent/WO2009050159A1/fr active Application Filing
- 2008-10-14 AR ARP080104473A patent/AR068988A1/es not_active Application Discontinuation
- 2008-10-14 CL CL2008003036A patent/CL2008003036A1/es unknown
- 2008-10-14 PE PE2008001765A patent/PE20091089A1/es not_active Application Discontinuation
- 2008-10-16 UY UY31400A patent/UY31400A1/es unknown

Also Published As

Publication number	Publication date
AR068988A1 (es)	2009-12-23
PE20091089A1 (es)	2009-08-24
TW200932243A (en)	2009-08-01
WO2009050159A1 (fr)	2009-04-23
UY31400A1 (es)	2009-05-29

Similar Documents

Publication	Publication Date	Title
CL2011002781A1 (es)	2012-05-25	Compuestos (e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol y (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol; composicion farmaceutica que los comprende; y uso en el tratamiento del cancer.
CL2008000795A1 (es)	2008-09-26	Uso de 1-[2-(2,4-dimetilfenilsulfanil)fenil)piperazina para el tratamiento del dolor o de los sintomas residuales de la depresion; y dicho compuesto.
CL2011002697A1 (es)	2012-06-01	Compuestos derivados de 3-[4-(oxo-dihidropiridin)bencil]-1,3-oxazin-ona hidratados, inhibidores 11beta-hsd1; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes
PE20071184A1 (es)	2007-11-30	Compuestos de aminoisoindolina para el tratamiento del lupus cutaneo
CL2011001224A1 (es)	2011-09-16	Compuestos derivados de benzofurano-3-carboxamida; composicion farmaceutica que los comprende; y su uso en tratamiento del virus de la hepatitis c.
GT200900260A (es)	2011-09-05	Terapia de convinacion anticoagulante con un compuesto que actua como inhibidor del factor xa
CO6592093A2 (es)	2013-01-02	Polimorfos y solvatos de clorhidrato de 4-(2-((5-metil-1-(2-naftalenil)-1h-pirazol-3-il)oxi9etil)morfolina
JO3062B1 (ar)	2017-03-15	R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
CL2007002967A1 (es)	2008-04-18	Forma cristalina a del compuesto 4-[3-(4-ciclopropancarbonil-piperazin-1-carbonil)-4-fluoro-bencil]-2h-ftalazin-1-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un
AR074471A1 (es)	2011-01-19	Compuesto 5(5-(2-(3-aminopropoxi) - 6 - metoxifenil) -1h- pirazol-3- ilamino ) pirazin -2-carbonitrilo , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para inhibir chk1 y para tratar cancer
CU20110213A7 (es)	2012-04-15	Sales de disacarina, ácido difumárico, ácido di-1-hidroxi-2-naftoico y ácido monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato de 4-(dimetilamino)butilo
PE20100083A1 (es)	2010-02-17	Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
UY31431A1 (es)	2009-05-29	Inhibidor de la proteina activadora de la 5-lipoxigenasa (flap)
ATE534632T1 (de)	2011-12-15	Thiazole, imidazole und pyrazole als proteinkinasehemmer
FR2901467B1 (fr)	2008-08-15	Prothese anatomique pour le traitement des hernies, telles que hernies inguinales et crurales et autres
NO20090834L (no)	2009-03-19	Anvendelse av azabicykloheksanderivater
MX2012006108A (es)	2012-07-03	Sales de 4-[2-[[5-metil-1-(2naftalenil)-1h-pirazol-3-il]oxi]etil]m orfolina.
NZ594556A (en)	2013-11-29	Carboxamide compounds and methods for using the same
IT1391866B1 (it)	2012-01-27	Composizione iniettabile di polinucleotidi per il trattamento di patologie osteoarticolari.
CL2007003672A1 (es)	2008-07-25	Compuestos derivados de heteroaril-pirrolidinil-cetona y heteroaril-piperidinil-cetona; composicion farmaceutica; y uso en el tratamiento de la depresion y ansiedad.
EA200970871A1 (ru)	2010-04-30	Новое терапевтическое применение 4-[2-(4-метилфенилсульфанил)фенил]пиперидина
ATE401891T1 (de)	2008-08-15	Verwendung von meloxicam-formulierungen in der veterinärmedizin
CL2009000665A1 (es)	2010-04-09	Compuestos derivados de pirrolidinilo; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la ansiedad, depresion o ambas.
CL2008003036A1 (es)	2009-05-08	Composicion farmaceutica acuosa que comprende 4-[(4-clorofenil)metil]-2-({(2r)-1-[4-(4-{[3-(hexahidro-1h-azepin-1-il)propil]oxi}fenil)butil]-2-pirrolidinil}metil)-1(2h)-ftalazinona; envase que la comprende; y uso para el tratamiento de enfermedades inflamatorias y/o alergicas tal como rinitis alergica.
MX2022007176A (es)	2022-08-25	4-((2-oxopyri din-1 (2h)-yl)metil)benzamidas para el tratamiento de la deficiencia de alfa1-antitripsina.